摘要
目的探讨神经生长因子对急性颅脑损伤患者血清S100β蛋白与白介素6(IL-6)水平的影响。方法选取2013年3月~2015年5月于天津港口医院脑外科治疗的急性颅脑损伤患者70例,按随机数字表法分组,对照组35例采取常规对症治疗,研究组35例在常规治疗基础上采用注射用鼠神经生长因子治疗,疗程为2周,在入院时、入院1周及入院2周时记录格拉斯哥昏迷评分(Glasgow coma scale,GCS)状况,采用ELISA法测定血清S100β与IL-6水平,同时对比脑水肿消除临床疗效。结果治疗2周后,对照组脑水肿消除总有效率77.14%低于研究组的94.29%,差异具有统计学意义(P〈0.05);研究组在入院2周时GCS评分显著低于对照组,研究组入院1、2周时血清神经元特异性烯醇化酶(neuron-specific enolase,NSE)和髓鞘碱性蛋白(myelin basic protein,MBP)水平、S100β蛋白和IL-6低于对照组,差异均具有统计学意义(P〈0.05)。结论采用神经生长因子能降低急性颅脑损伤患者血清S100β与IL-6水平,缓解炎症状态,效果显著。
Objective To investigate the effect of nerve growth factor on the levels of serum S100 protein and interleukin-6( IL-6) in patients with acute brain injury. Methods 70 cases with acute craniocerebral injury from March 2013 to May 2015 in department of cerebral surgery of Tianjin port hospital were selected and divided into two groups according to random number method. The control group( 35 cases) received conventional symptomatic treatment,the study group( 35 cases) received conventional treatment on the basis of mouse nerve growth factor for injection,with a consecutive treatment of two weeks. On admission,one and two weeks after admission,the Glasgow coma scale( GCS) score was recorded,serum S100 beta protein and IL-6 levels were measured by enzyme-linked immunosorbent assay( ELISA) and the clinical curative effect of cerebral edema eliminate was compared. Results After two weeks' treatment,the total efficacy in control group was lower than that in study group( 77. 14% vs. 94. 29%)( P〈0. 05). The GCS score of two weeks after admission in study group was lower than that in control group,serum levels of neuron-specific enolase( NSE),myelin basic protein( MBP),S100β protein and IL-6 of one and two weeks after admission in study group were lower than those in control group( P〈0. 05). Conclusion The nerve growth factor could decrease the levels of serum S100β and IL-6 and alleviate inflammation in patients with acute craniocerebral injury and the effect is obvious.
出处
《中国生化药物杂志》
CAS
2016年第4期167-169,共3页
Chinese Journal of Biochemical Pharmaceutics